🇪🇺 Nelfinavir (NFV) in European Union

EMA authorised Nelfinavir (NFV) on 22 January 1998

Marketing authorisation

EMA — authorised 22 January 1998

  • Application: EMEA/H/C/000164
  • Marketing authorisation holder: Roche Registration Ltd.
  • Local brand name: Viracept
  • Indication: Viracept is indicated in antiretroviral combination treatment of human-immunodeficiency-virus (HIV-1)-infected adults, adolescents and children of three years of age and older. In protease-inhibitor (PI)-experienced patients, the choice of nelfinavir should be based on individual viral resistance testing and treatment history.
  • Status: withdrawn

Read official source →

Nelfinavir (NFV) in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Infectious Disease approved in European Union

Frequently asked questions

Is Nelfinavir (NFV) approved in European Union?

Yes. EMA authorised it on 22 January 1998.

Who is the marketing authorisation holder for Nelfinavir (NFV) in European Union?

Roche Registration Ltd. holds the EU marketing authorisation.